Chronic tracheoesophageal fistula successfully treated using Amplatzer septal occluder

Tracheoesophageal fistula (TEF) is a serious life-threatening condition that appears in critically ill patients with a prolonged history of mechanical ventilation. Enteral feeding and dietary support combined with surgery is the gold standard. In selected patients, TEF healing can be ensured by a mini-invasive approach using an Amplatzer septal occluder (AGA Medical Corporation), intended for cardiac septal defect closure [1]. The Amplatzer septal occluder, which is composed of a nitinol mesh, has two self-expandable disks connected by a thin diameter waist (▶Fig. 1) and ensures mechanical closure of the two sides of the fistula, making a potential platform for subsequent tissue ingrowth [2].

This technique was used in a 44-year-old man with tracheostomy and a history of protracted invasive lung support. He had been diagnosed as having a TEF after numerous episodes of aspiration pneumonitis and had subsequently undergone anterior cervicotomy with surgical closure of the fistula. After 7 months, his dysphagia relapsed. Endoscopy confirmed recurrence of the TEF (▶Fig. 2), which was initially treated unsuccessfully by submucosal injection of acrylic glue. Given the poor clinical condition of the patient and the failure of both surgical and endoscopic therapy, it was decided to try positioning of an Amplatzer septal occluder (▶Video 1). The procedure was performed using a gastroscope (GF-1TH190; Olympus Europe) and a bronchoscope (BF-1T180; Olympus Europe). The TEF was cannulated using a papillotome (TRUEtome; Boston Scientific) and a 0.025-inch guidewire (Jagwire; Boston Scientific) was inserted into the bronchial segment. The wire was then grasped with a biopsy forceps (Endo-Jaw; Olympus Europe) passed through the bronchoscope, providing countertraction by maintaining a straightened position. The septal occluder catheter was introduced and the two ends were released into the trachea and esophagus, respectively (▶Fig. 3). Successful closure of the TEF was confirmed by contrast medium injection (▶Fig. 4). The procedure was uneventful.
Repeat endoscopy 4 weeks later showed that the stent remained in the correct position and the patient has remained asymptomatic during 12 months of follow-up.

In selected tertiary care centers, where advanced endoscopic and catheter lab suites are available, placement of an Amplatzer septal occluder is feasible and safe [3, 4], offering potential fistula closure, especially in patients in a critical condition, with severe comorbidities and recurrence of a TEF.

Competing interests

None

The authors

Mario Traina1, Michele Amata1, Lavinia De Monte2, Antonino Granata1, Dario Ligestri1, Ilaria Tarantino1, Caterina Gandolfo2

1 Endoscopy Service, Department of Diagnostic and Therapeutic Services, IRCCS – ISMETT, Palermo
2 Thoracic Surgery, Department of Diagnostic and Therapeutic Services, IRCCS – ISMETT, Palermo
3 Cardiac Cath Lab, Department of Diagnostic and Therapeutic Services, IRCCS – ISMETT, Palermo

Corresponding author

Michele Amata, MD
Endoscopy Service, IRCCS – ISMETT, Via Tricomi, 5, 90127 Palermo, Italy
Fax: +39-091-2192400 (specify Endoscopy Service)
mamata@ismett.edu

References


Bibliography

DOI https://doi.org/10.1055/a-0677-1531
Published online: 10.9.2018
Endoscopy 2018; 50: 1236–1237
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0013-726X

Acknowledgments

The authors gratefully acknowledge the contribution of Federico Amata for his graphic support.